Data Sheet (Cat.No.T9370)

TargetMol

dCBP-1

Chemical Properties



CAS No. : 2484739-25-3

Formula: C51H63F2N11O10

Molecular Weight: 1028.11

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.
Targets(IC50)	Epigenetic Reader Domain,PROTACs
In vitro	Treatment of the human haploid cell line HAP1 for 6 h with dCBP-1 revealed almost complete loss of both CBP and p300 between 10 and 1,000 nM doses. A time course analysis with 250 nM dCBP-1 revealed almost complete degradation of p300/CBP within an hour of treatment[1]. dCBP-1 was also able to induce near-complete p300/CBP degradation across other multiple myeloma cell lines tested, including MM1R, KMS-12-BM, and KMS34[1].

Solubility Information

Solubility	DMSO: 50 mg/mL (48.63 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (1.95 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.9727 mL	4.8633 mL	9.7266 mL
5 mM	0.1945 mL	0.9727 mL	1.9453 mL
10 mM	0.0973 mL	0.4863 mL	0.9727 mL
50 mM	0.0195 mL	0.0973 mL	0.1945 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Raghu Vannam, et al. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell Chem Biol. 2020 Dec 31;S2451-9456(20)30513-4.
Liu L, Deng P, Liu S, et al.Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma.Cell Death & Disease.2023, 14(8): 513.
Zhang D, Ma B, Liu D, et al.Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy.EBioMedicine.2024, 105.